National Institute for Medical Research, Divisions of Molecular Neuroendocrinology (P.L.T., D.F.C., P.H., C.M., I.C.A.F.), Neurophysiology (S.L., A.K.S., D.O.), and Biological Services (K.M.), The Ridgeway, London NW7 1AA, United Kingdom; and Department of Structural and Cellular Biology (C.J.P.), Tulane University School of Medicine, New Orleans, Louisiana 70112-2699
Address all correspondence and requests for reprints to: Professor Iain C. A. F. Robinson, Division of Molecular Neuroendocrinology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. E-mail: irobins{at}nimr.mrc.ac.uk.
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have previously engineered a rat GHRH cosmid that efficiently targets a variety of transgene products to GHRH neurons (7, 8). Like all central nervous system neurons, the activity and survival of GHRH cells are dependent on the maintenance of resting membrane potential and ion fluxes through ion channels, and this can be manipulated by overexpression of heterologous ion channels to silence or ablate cells (9, 10, 11). In this report, we describe the first application of such a transgenic ion-channel strategy with the aim of silencing or ablating neuroendocrine cells.
The strategy we chose is based on H37AM2, a variant of the influenza M2 viral protein that forms a homotetrameric monovalent cation channel in mammalian cells that can be blocked by the antiinfluenza drug rimantadine (12, 13, 14). The 37His residue is important for ion specificity; mutation of this residue to 37Ala broadens the specificity of the channel to other monovalent cations and reduces the pH sensitivity of the channel but retains its sensitivity to blockade with rimantadine (Ogden, D., unpublished). When expressed in mammalian cells in vitro, H37AM2 is conditionally lethal; it kills cells unless they are cultured in the presence of rimantadine (11). When expressed in transgenic mice from a T-cell-specific p56Lck promoter, H37AM2 irreversibly ablated a cell lineage in the developing immune system (11). We have now made a modified version of this H37AM2 channel construct and confirmed, using whole cell patch clamp techniques, that it generated a reversible rimantadine-sensitive monovalent cation conductance when expressed in an endocrine cell line in vitro. This channel construct was then cloned into a 38-kb rat GHRH cosmid, which was used to generate transgenic mice expressing H37AM2 in GHRH neurons. The resulting GHRH-M2 mice provide the first genetic model of specific hypothalamic GHRH deficiency caused by ionic ablation of GHRH neurons. They exhibit the expected severe secondary GH deficiency and dwarfism but also unexpected defects in prolactin (PRL) production. Some of these results have recently been reported in preliminary form (15).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
Generation of GHRH-M2 Transgenic Mice
This H37AM2 construct was then cloned into a 38-kb rat GHRH promoter construct (Fig. 3A) and used to generate transgenic mice. Three founders were identified; one was infertile, but from two others, stable lines were established (lines I and J). Both lines showed a similar phenotype, and all the results presented will be from line I, comparisons being made between GHRH-M2 and nontransgenic (NT) littermates, unless otherwise stated. Hemizygous males and females were fertile, with normal litter sizes, but their transgenic progeny were severely dwarfed compared with NT littermates (Fig. 3B
). For the first 2 postnatal weeks, there was no difference in size (Fig. 3C
), but from 3 wk onwards, GHRH-M2 animals grew more slowly than their NT littermates, attaining only 60% of their weight by 6 wk of age (Fig. 3C
), and remaining dwarfed in adulthood (Table 1
). Measurements of pituitary GH contents showed that adult GHRH-M2 mice had severe GH deficiency (GHD) compared with their NT littermates (Table 1
).
|
|
|
H37AM2 transcripts could be detected by RT-PCR in hypothalamic, testicular, and renal RNA from transgenic but not NT animals (Fig. 5). Although GHRH expression was virtually eliminated, as assessed by ICC or in situ hybridization, residual GHRH transcripts could still be amplified by RT-PCR, using specific primers for transcripts from both the hypothalamic and placental promoters (Fig. 5
). Expression of both classes of transcript was evident in hypothalamus and placenta from both GHRH-M2 and NT mice, whereas placental but not hypothalamic transcripts were detected in testis. No GHRH or M2 expression was observed in spleen. Pituitary GH, PRL, and TSH contents were measured in two groups of female GHRH-M2 and NT mice at 14 and 42 d of age (Fig. 6
). Specific GH deficiency was already evident at 14 d. PRL content was unaffected at 14 d but was significantly lower in the GHRH-M2 transgenic mice by 42 d. The effect of lower pituitary PRL content on relative lactational performance was not determined, but milk production was sufficient for hemizygous transgenic females to raise litters of a normal size. ICC showed a normal distribution of a reduced number of PRL+ve cells in the hypoplastic GHRH-M2 anterior lobe (data not shown). TSH content in the same extracts was unaffected at either age (Fig. 6
). Measurements in other groups of mice showed that pituitary GH contents were already significantly lower in GHRH-M2 mice by 7 d of age (1.06 ± 0.12 µg vs. 2.45 + 0.33 µg in NT littermates, P < 0.01), well before their dwarfism was apparent.
|
|
|
|
Finally, we tested whether rimantadine could block or reduce ablation or silencing of GHRH neurons in GHRH-M2 mice if animals were treated from an age before GHRH (and therefore the transgene) is expressed. Treatment of transgenic and NT mice from 3 d before birth and continuing this treatment for a further 5 wk, by addition of rimantadine to the drinking water of lactating mothers and for 2 wk after weaning, failed to prevent the reduction in pituitary GH content in GHRH-M2 transgenic animals (3.2 ± 0.2 µg vs. 58.0 ± 8.7 µg in NT littermates, P < 0.001). We also treated pregnant mothers from 2 d after mating by addition of rimantadine to the drinking water, to deliver the drug in utero to transgenic and NT mice from an earlier age, and measured pituitary GH content of 1 d old offspring. At this age, no reduction in pituitary GH content was found in transgenic animals with or without rimantadine treatment compared with NT littermates (transgenic with rimantadine, 414.3 ± 58.1 ng (n = 6); transgenic without rimantadine, 537.1 ± 86.2 ng (n = 12); NT, 441.3 ± 57.5 ng (n = 12), no significant differences).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Instead of an irreversible GHRH gene knockout approach, we chose a transgenic strategy using ion channels with the potential to reversibly silence disrupt, or ablate neuroendocrine neurons. Transgenic expression of homologous or heterologous K+ ion channels has been used to alter the activity of several types of excitable cells (26, 27, 28), but drugs cannot be used to control the conductance of these channels selectively because the same or related channels are present in many other cells. However, by using ion channels derived from nonmammalian systems, one can take advantage of drugs that act on these transgene channels specifically at doses that minimally affect mammalian channels (10, 11), in attempts to regulate the conductance of the transgene ion channel selectively.
The ion channel we chose is based on the influenza virus M2 protein (13, 29), which has several advantages for use as a transgene. M2 is a simple single chain 97-residue protein with a single transmembrane domain that, when expressed in mammalian cells, assembles to form a pH-sensitive homotetrameric proton channel in the plasma membrane that can be blocked by the antiinfluenza drugs, amantidine, and rimantadine (30, 31, 32). The ionic specificity of M2 could be broaden to monovalent cations by a single amino acid mutation, and expression of this H37AM2 variant was known to kill mammalian cells unless they are cultured in the presence of rimantadine; furthermore, expression in transgenic animals leads to ablation of cells in which it is expressed (11).
For our transgene construct, H37AM2 was inserted into the backbone of an hGH expression cassette to provide transcriptional intron splicing and translational signals used previously to express other products in both GHRH and GH cells (8, 16, 17). It was also flanked with an MluI linker, so it could be inserted into the unique MluI cloning site previously introduced (7) into the hypothalamic promoter of the rat GHRH (rGHRH) cosmid. The N-terminal sequences of the GH signal peptide and H37AM2 are fortuitously similar, so it was possible to introduce H37AM2 in such a way that the first intron in the GH expression cassette could be retained, while adding only a small heptapeptide N-terminal tag to H37AM2 in the final splice product. Other mutational studies with M2 (Hay, A., National Institute for Medical Research; personal communication) suggested that this would likely be tolerated well without compromising channel assembly, conductance, or rimantadine sensitivity, but we sought to confirm this by expressing the modified H37AM2 construct in cell lines in vitro before making transgenic animals.
When transfected into GC cells, H37AM2 immunoreactivity was readily detected in the cell membranes by immunofluorescence and Western blotting. Using cotransfection with eGFP, transfected cells could be identified and subjected to patch-clamp analysis for measurements of H37AM2 channel activity. These confirmed the presence of high conductance ion channels in cells cotransfected with H37AM2, but not in untransfected GC cells or cells transfected with eGFP alone. The channel properties conformed closely with those known for unmodified H37AM2 channels expressed in other cells (Ogden, D., unpublished), providing a broad specificity noninactivating monovalent cation conductance at physiological pH, which could be blocked in a dose-dependent and reversible fashion by rimantadine (32).
We then generated transgenic mice expressing this heptapeptide-tagged H37AM2 channel protein in GHRH neurons. Two lines of mice were established, both of which showed severe GH deficiency and dwarfism. When coronal sections of brains were examined for GHRH mRNA or peptide expression by in situ hybridization or immunocytochemistry, GHRH-M2 mice were essentially devoid of the GHRH expression readily detectable in WT hypothalamic ARC. This was clearly not secondary to GH deficiency, which would cause an increase of GHRH expression (33), as was evident when GHRH-M2 sections were compared with those from a different transgenic mouse line with primary GH deficiency (16). Any increased drive to GHRH gene expression caused by GH deficiency in GHRH-M2 mice, would also drive more GHRH-H37AM2 expression, increasing the disruption of GHRH neurons.
Although no GHRH mRNA or peptide could be detected in GHRH-M2 mice by in situ hybridization or immunocytochemistry, both GHRH and H37AM2 transcripts could be detected in hypothalamic extracts when RT-PCR was used. It is likely that the RT-PCR is detecting transcripts found in other regions of the hypothalamus (see below) and/or transcripts that have not yet been inactivated or ablated.
H37AM2 transcripts could also be detected by RT-PCR in the testis and kidney of GHRH-M2 mice. Although GHRH expression has been reported in both of these tissues (34, 35), no transcripts could be found from the hypothalamic promoter in testes (34) and, in this study, hypothalamic transcripts were not detected by RT-PCR in either tissue. In contrast, placental expression of GHRH from the hypothalamic promoter was detected by RT-PCR, but H37AM2 expression was not. Ectopic kidney and testis H37AM2 expression and failure of placental expression shows that even this 38kB promoter cosmid must lack of all the locus control sequences necessary for complete position-independent, tissue-specific GHRH expression in our construct. Similar kidney ectopic expression was also found in some other transgenic lines generated with this rGHRH cosmid (8). Relative to hypothalamic expression, however, testicular or kidney expression of M2 from the hypothalamic promoter is likely to have been at very low levels or in a small subset of cells because only low levels of hypothalamic expression have been found in these tissues (35, 36). Because we were able to routinely breed from male GHRH-M2 transgenic mice, the testicular expression of M2 does not appear to compromise fertility.
Crossing the GHRH-M2 mice with GHRH-eGFP mice (8), in which eGFP was driven from the same GHRH transgene promoter, confirmed the results from in situ hybridization and ICC. No GHRH-eGFP cells were visible throughout the entire ARC in the double transgenic progeny compared with the hundreds of cells visible in the GHRH-eGFP mice. Taken together with the GH deficiency and dwarfism, we believe that essentially all of the arcuate hypothalamic GHRH population has been functionally silenced, and most likely ablated (see below), by the expression of the H37AM2 ion channel. In the course of these experiments, a population of fluorescent eGFP-positive cells was seen in singly transgenic GHRH-eGFP mice in the dorsal paraventricular nucleus at the top of the third ventricle (data not shown). These cells persist in doubly transgenic GHRH-eGFP/GHRH-M2 mice, presumably because they are less sensitive to the effects of the M2 transgene expression or M2 protein levels are lower in these cells.
The GH cell hypoplasia and pituitary GH deficiency in GHRH-M2 mice confirms the physiological importance of GHRH in proliferation of somatotrophs, and in stimulation of GH gene transcription and release (3). Ghrelin (37), another potential endogenous physiological GH secretagogue, clearly cannot functionally compensate for the loss of GHRH in GHRH-M2 mice. GHRH injections were effective in stimulating GH release in GHRH-M2 mice showing that functional GHRH receptors (38) were maintained in the residual somatotrophs of GHRH-M2 mice despite the chronic lack of GHRH. That GHRP-6 (39) injections were less effective was not surprising because the in vivo responses to GH secretagogues and ghrelin are known to synergize with GHRH (40), and blockade of GHRH by immunoneutralization (41) greatly diminishes the in vivo GH response to GH secretagogues.
Continuous short-term GHRH infusions are not very effective in stimulating growth in rodents (42), but do stimulate GH synthesis (2). Similar results were observed with a 7-d continuous sc GHRH treatment of GHRH-M2 mice, which showed no significant effect on growth over this period but doubled pituitary GH content. Clearly, the residual pituitary GH cell population could still respond to the trophic effects of exogenous GHRH. It may be worth noting that if humans with true GHRH deficiency exist, our results would predict that they might be detected by a poorer response to GH secretagogues than to GHRH itself, unlike GHRH-receptor deficient subjects (43, 44).
The GH deficiency in GHRH-M2 mice was not apparent in 1-d-old animals, consistent with the GHRH-independent somatotroph development described in lit/lit mice (18). However, GH deficiency was evident as early as 7 d, well before the growth reduction was apparent, and became progressively more severe. One surprise was the reduction in pituitary PRL in GHRH-M2 mice, which appeared with a delay relative to GH deficiency. A modest reduction would perhaps be expected in view of the marked hypoplasia of GH cells which share a common lineage with PRL cells, and some (7, 16) though not all (45, 46) rodent models with GH deficiency and somatotroph hypoplasia also exhibit some PRL deficiency. Many effects of GHRH may be mediated via the activation of Pit1 (18, 47), but reductions in this transcription factor are unlikely to explain the reduced PRL contents in GHRH-M2 mice per se, because there were no reductions in TSH, which is also Pit1 dependent (47).
Because GHRH has little or no direct effect on PRL synthesis or release (48) and normal pituitary PRL content was found in mice with a disruption of the GHRH gene (6), the degree of PRL deficiency in GHRH-M2 mice was surprising. If GHRH is the only hypophysiotropic product of the GHRH neuron and is the exclusive ligand for the GHRH receptor, one would expect the phenotypes of deficiencies in GHRH ligand (GHRH-M2 mice) and its receptor (lit/lit mice) to be similar. However, the effect on PRL in GHRH-M2 mice appears more severe than would be predicted from the relative transcript abundance of GH and PRL in lit/lit mice (49), although good comparative assay data on pituitary PRL and GH protein levels in lit/lit mice are still lacking. GHRH-overexpressing transgenic animals have mild lactotroph hyperplasia but no increase in total pituitary PRL content (50). Perhaps the most telling comparison is the recently reported data from a mouse with a targeted disruption of the GHRH locus that eliminated GHRH expression but not other products of the GHRH gene (6), causing a specific reduction in GH, but not PRL.
Because our approach ablates the GHRH neuron, rather than disrupting the GHRH peptide per se, and because GHRH infusions increased GH but not PRL contents (albeit over the short term), we have to consider the possibility that the GHRH peptide is not the sole hypophysiotropic product of the GHRH neuron. In line with this, targeted disruption of the homeobox gene GSH-1, which is required for normal GHRH neuron development, also leads to a similar phenotype of both GH and PRL cell hypoplasia (23). GSH-1 has been shown to be required for GHRH gene expression in the hypothalamus (51), but in this model it is unclear whether the reduction in pituitary PRL content was caused by a disruption of normal GHRH neuron development, or through effects on the many other cell types normally expressing GSH-1. Our results, from specific ablation of GHRH neurons, are consistent with abnormal GHRH neuron development causing the broader pituitary effects described in animals with disrupted GSH-1.
Many other active peptides have been colocalized with GHRH in the ARC, but the more obvious candidates for additional hypophysiotropic activities from this neuron are peptides (GHRH-RP and p7592NH2) that are coproduced with GHRH as part of the same polypeptide precursor, transported to the median eminence and probably cosecreted with GHRH (52). GHRH-RP has GHRH-independent effects in other tissues (53), and both GHRH-RP and p7592NH2 activate MAPK (54) in GH3 cells that produce both PRL and GH. This activity would be missing after GHRH neuronal ablation in GHRH-M2 mice, whereas it would be increased in lit/lit mice, because their GHRH gene expression is enhanced in the absence of GH feedback. In this context, it is interesting that PRL levels are unchanged in GHRH-knockout mice recently described by Alba and Salvatori (6) because these mice are still able to produce some GHRH-RP and p7592NH2-related products, at least in testis. It will be interesting to know what effect the targeted deletion has had on hypothalamic levels of these GHRH-precursor-derived peptides.
Apart from the pituitary phenotype and dwarfism, the GHRH-M2 mice were otherwise apparently healthy, as were the GHRH knockout mice (6). It is therefore curious that no human GHRH mutation has yet been reported because it might be expected to generate a nonlethal but readily apparent autosomal recessive familial form of fertile dwarfism. Complete GH deficiency is not embryonic-lethal in animals or humans, but because the GHRH gene encodes other biologically active peptides (52) and is expressed from different promoters in tissues other than hypothalamus (34), it is conceivable that a global GHRH gene deletion might be embryonic lethal from other causes, whereas a hypothalamic ablation of GHRH cells, only occurring once the cells have differentiated to express GHRH from the hypothalamic promoter, is clearly nonlethal. Because other biologically active peptide products of the GHRH gene may still be normally expressed in GHRH-KO animal, it is possible that GHRH mutations leading to a premature stop codon, which would result in the absence of these peptides, could be embryonic-lethal in humans.
The advantage of this ion channel approach in vitro is that the increased conductance that depolarizes and silences excitable cells, can be reversed by exposure to rimantadine which blocks the H37AM2 channels. The ablation strategy using M2 channels was first tested in the developing immune system (11) in which is was an efficient ablator, but the conditional reversibility in vitro did not extend to a successful conditional strategy in vivo. In this study, H37AM2was expressed in rapidly dividing cells early in embryonic development, and treatment with rimantadine in vivo was not successful in preventing or reversing the immune cell ablation (11). However, we hoped that driving H37AM2 from a GHRH promoter expressed late in development (55) and in nondividing differentiated neurons, rimantadine treatment might provide some control over cell ablation and excitability in surviving GHRH neurons. This did not prove to be the case: under in vivo conditions, H37AM2 expression irreversibly ablated GHRH cells, and no recovery was seen after rimantadine treatment. The cell ablation by H37AM2 could not be blocked with rimantadine treatment of transgenic animals in utero and through neonatal development, possibly because of inadequate delivery of the drug across placental and mammary barriers.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For in vitro transfection experiments, the H37AM2 cassette was inserted into a modified version of the mammalian CMV expression vector pcDNA 3.1 (Invitrogen, Paisley, UK) to give pcDNA 3.1-M2 (Fig. 1A). In some experiments, this was cotransfected with a CMV vector expressing eGFP (Fig. 1C
) (pEGFP-N2, BD Biosciences, Oxford UK) (17). For transgenesis (Fig. 3A
), the H37AM2 MluI cassette was cloned into a unique MluI site in the 5' of the first hypothalamic exon of GHRH, in a 38-kb rat cosmid, containing 16 kb 5' and 14-kb 3' flanking sequences, as previously described (7, 8).
Cell Culture and Transfection
GC cells (17) were cultured in DMEM supplemented with 15% horse serum, 5% fetal calf serum, 1% penicillin-streptomycin, and 1% l-glutamine (Invitrogen) at 37 C under 5% CO2. They were maintained at 3040% confluency for no more than 18 passages. One day before transfection, cells were plated on poly-SD-lysine-coated glass coverslips in 60-mm cell culture dishes at a density of 3 x 105 per dish. Cells were transfected with Superfect (QIAGEN, Crawley, UK) according to manufacturers instructions, using 1.1 µg pcDNA 3.1-M2 plasmid DNA alone or as a mixture with the eGFP plasmid (0.6 µg pEGFP-N2 + 0.5 µg pcDNA 3.1-M2). After 2.5 h, the DNA suspension was removed and the cells rinsed with complete growth medium containing 23100 µM rimantadine (Sigma-Aldrich, Gillingham, UK), and maintained in rimantadine-containing medium for 48 h before experimentation. Stably transfected cell lines were selected in G-418 (250 µg/ml; Invitrogen) and rimantadine (23 µM).
Electrophysiology
After cotransfection with H37AM2 and eGFP, GC cells were examined under light and fluorescence microscopy. Cells with as few other cell contacts as possible were subjected to whole-cell voltage-clamp via a single patch electrode using an Axopatch 1d amplifier, Digidata 1200 interface and pClamp6 software (Axon Instruments, Union City, CA). Data were low-pass filtered at 2 kHz and sampled at 5 kHz. Borosilicate glass pipettes with tip resistances of 36 M were filled with: Cs gluconate (130 mM), CsCl (15 mM) HEPES (15 mM), EGTA (5 mM), MgCl2 (2 mM), Na-ATP (2 mM), and phosphocreatine (2 mM); adjusted to pH 7.3 using CsOH, with a final solution osmolarity around 315 mOsm.
Cells were bathed first in Na-free extracellular recording solution: N-methyl-D-glucamine (NMDG) (138 mM), HCl (130 mM), glucose (20 mM), HEPES (18 mM), CaCl2 (2 mM) and MgCl2 (1 mM), pH 7.3, and 290 mOsm. A fixed prepulse inactivation protocol was applied from a holding potential of 50 mV, and steady-state currents were recorded from the end of the first step (Fig. 2A). Recordings were then repeated after exchanging the extracellular solution for one containing Na+: NaCl (130 mM), glucose (20 mM), HEPES (10 mM), Na-HEPES (10 mM), CaCl2 (2 mM) and MgCl2 (1 mM), pH 7.3, and 300 mOsm. Single concentrations of rimantadine were applied to each cell via this solution and remaining steady-state currents remeasured as a percentage of control currents. Potentials given are not corrected for a liquid junction potential calculated as 19 mV bath pipette.
Generation and Analysis of GHRH-M2 Transgenic Mice
All animal experiments were carried out in accordance with our Institutional and National guidelines. The rGHRH-H37AM2 DNA insert was released from the cosmid by digestion with NotI, purified by ultracentrifugation in a 520% salt gradient, and brought to a concentration of 15 ng/µl in 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA (pH 8.0). Transgenic mice were generated by pronuclear microinjection of this construct into fertilized oocytes of superovulated (CBA/Ca x C57BL/10)F1 mice followed by oviductal transfer into pseudopregnant recipients. Genomic DNA from tail biopsies was amplified by PCR using primers 5'-AACCACTCAGGGTCCTGTGGACAG-3' and 5'-ATGATGCAACTTAATTTTATTAGGACAA-3', for the hGH 5'- and 3'-UTR sequences flanking the H37AM2 transgene. All lines were maintained as hemizygous, with NT littermates serving as controls for the transgenic animals. Some GHRH-M2 animals were crossed with animals from another transgenic line expressing eGFP in GH cells (17) or a line expressing eGFP in GHRH neurons (8). From the resulting progeny, pituitaries and brains were fixed, 12-µm sections were cut and examined for eGFP fluorescence.
RT-PCR
RNA was extracted from hypothalamus, testis, placenta, kidney, and spleen using Trizol reagent (Invitrogen), treated with RQ1 ribonuclease-free deoxyribonuclease (Promega, Southampton, UK) for 60 min at 37 C and repurified using Trizol reagent. RNA (15 µg) was transcribed in a 20-µl reaction volume with 200 U reverse transcriptase (SuperScriptIII, Invitrogen) in 1x first-strand buffer supplemented with 10 pmol oligo(deoxythymidine)17 0.5 mM deoxynucleotide triphosphates (Amersham Pharmacia Biotech, Chalfont St. Giles, UK), 40 U ribonuclease Inhibitor (Promega) and 5 mM dithiothreitol. The mixture was incubated at 50 C for 45 min, then 55 C for 15 min and the cDNAs amplified by PCR. For the transgene product, the primers were those used for genotyping, to amplify from cDNA, a predicted fragment size of 464 bp. For GHRH, two forward primers were used: 5'-GGTCAGTGGGACCTGAGCAG-3' for hypothalamic promoter transcripts and 5'-CGCAGGTCTCTCCTGGTTGC-3' for placental promoter transcripts; in both cases the reverse primer was: 5'-CTGTCCACATGCTGTCTTCC-3'. These would generate predicted fragment sizes of 317 and 316 bp for hypothalamic and placental transcripts, respectively. Mouse GAPDH (glyceraldehyde-3-phosphate dehydrogenase) transcripts were amplified as internal controls.
In Situ Hybridization
Antisense and sense riboprobes corresponding to mouse GHRH cDNA (Image clone 1496474, see (8) and to H37AM2 transgene transcripts were labeled with either [35S]-uridine triphosphate or digoxigenin and in situ hybridizations were performed on cryostat sections prepared and developed as previously described (8, 33). Sections were also obtained from a transgenic mouse with somatotroph-specific expression of an exon-3-deleted isoform of hGH that causes primary pituitary GH deficiency and results in increased GHRH expression (16).
ICC
GC cells were fixed in 2% paraformaldehyde, permeabilized using Triton X-100 (0.1%; Sigma) and incubated with an antibody (R229/95) that recognizes the C terminus of M2 (courtesy of Dr. Alan Hay). After washing, antibody labeling was visualized with goat antirabbit IgG conjugated to tetramethylrhodamine isothiocyanate (Sigma). The same antibody was used for immunodetection of extracts from both stable and transiently transfected GC cell lines on Western blots, and confirmed the presence of a major protein band corresponding to the H37AM2 protein. ICC was performed for mouse GH and PRL on pituitary sections as previously described (16). For mouse GHRH on hypothalamic sections brains of WT and GHRH-M2 transgenic mice, fixed by perfusion with buffered 4% paraformaldehyde/0.25% glutaraldehyde, were sectioned frozen in the coronal plane at 30 µm. Sections from each 180-µm interval were immunostained using a rabbit polyclonal antiserum directed against mouse GHRH specifically (gift from Dr. F. Talamantes) diluted 1:20,000. Further processing used biotinylated secondary antiserum and avidin-biotin/peroxidase reagents (Vector Laboratories, Burlingame, CA) with reduced diaminobenzidene as brown chromogen (56).
RIAs
Pituitary tissues were homogenized and assayed for GH, PRL, and TSH using mouse-specific RIA reagents kindly provided by A. L. Parlow and the National Hormone and Pituitary Program, as previously described (16).
In Vivo Experiments
Body weights and lengths were recorded in age-matched littermates, housed in groups with ad libitum access to food and water. To test pituitary responses to GH secretagogues, groups of 5 transgenic and NT H37AM2 mice were anesthetized with sodium pentobarbital (25 mg/kg ip) a jugular vein catheterized and 50 µl blood samples withdrawn before, 5 and 15 min after iv injection of 500 ng GHRP-6 (Ferring AB, Malmo, Sweden) After 90 min, further blood samples were withdrawn before and after iv injection of 100 ng GHRH (human GHRH 27Nle(129)NH2; Bachem, Merseyside, UK). Plasma was obtained by centrifugation and assayed for mouse GH. In another experiment, groups of GHRH-M2 transgenic and NT mice were injected twice daily with 50 µg GHRH sc for 7 d, their weights recorded and their pituitary GH and PRL contents measured. Rimantadine (1 mg/ml) was added to the drinking water of other groups of GHRH-M2 mice or their mothers at various ages.
Data Analysis
Unless otherwise stated, data are shown as mean ± SEM. Differences between groups were analyzed by Students t test, with P < 0.05 taken as significant.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
FOOTNOTES |
---|
Current addresses for P.H.: Molecular and Cellular Neuroscience, Imperial College, Hammersmith Hospital, Du Cane Road, London W6 0NN, United Kingdom.
First Published Online January 20, 2005
Abbreviations: ARC, Arcuate nucleus; CMV, cytomegalovirus; eGFP, enhanced green fluorescence protein; GHD, GH deficiency; GSH1, GS homeobox 1; hGH, human GH; ICC, immuncytochemistry; n.s., not significant; NT, nontransgenic; PRL, prolactin; rGHRH, rat GHRH; UTR, untranslated region.
Received for publication June 1, 2004. Accepted for publication January 11, 2005.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|